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Targeted immune-modulating treatment with biological agents has revolutionized the
management of immune-mediated inflammatory diseases, including rheumatologic
conditions. The efficacy and tolerability of biological agents, from the initial tumour
necrosis factor (TNF)-α inhibitors to the new anti-cytokine monoclonal antibodies,
have dramatically changed the natural history of debilitating conditions such as
rheumatoid arthritis and seronegative spondyloarthropathies. The widening use of
biologics across several rheumatologic diseases has been associated with a new class
of adverse events, the so-called paradoxical reactions. These events are inflammatory
immune-mediated tissue reactions, developing paradoxically during treatment of
rheumatologic conditions with targeted biologics that are commonly used for treating
the idiopathic counterparts of these drug-induced reactions. The skin is frequently
involved, and, even if considered rare to uncommon, these cutaneous manifestations
are an important cause of biologic agent discontinuation. TNF-α antagonist-induced
psoriasis, which can manifest de novo or as exacerbation of a pre-existing form, is
the prototypic and most frequent paradoxical skin reaction to biologics while other
reactions, such as eczematous and lichenoid eruptions, hidradenitis suppurativa,
pyoderma gangrenosum, Sweet’s syndrome and granulomatous skin diseases, occur
much more rarely. Management of these reactions consists of topical or systemic
skin-directed therapies, depending on the severity and extension of the cutaneous
picture, and it is generally associated with switching over to other disease-modifying
regimens for treating the underlying rheumatologic condition. Here, we review in detail
the current concepts and controversies on classification, pathogenesis and clinical
management of this new class of cutaneous adverse events induced by biologics in
rheumatologic patients.
Keywords: paradoxical skin reactions, biologics, rheumatological disorders, psoriasis, TNFα-inhibitors
Abbreviations: IFN, Interferon; IFN type-1, interferon-type 1; IL, interleukin; IL-10, interleukin 10; ILC, innate lymphoid
cell; iTreg, induced regulatory T-cells; NDs, neutrophilic dermatoses; TGF-β, transforming growth factor-beta; Th, T helper
cell; TNF-α, tumor necrosis factor-alpha; TNFR2, tumor necrosis factor receptor 2; Tregs, regulatory T-cells.
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INTRODUCTION
Targeted biological agents have dramatically changed the
treatment landscape of immune-mediated inflammatory
diseases (IMIDs) with rheumatological conditions being at
the front of this revolution. The efficacy and tolerability
of targeted biological agents have determined a paradigm
shift in the treatment of several rheumatologic conditions,
modifying the natural history of progressive, invalidating
disease, such as rheumatoid arthritis (RA) and seronegative
spondyloarthropathies (SpA). While biological agents (BA)
have a superior safety and tolerability profile compared
to conventional disease-modifying anti-rheumatic drugs
(DMARDs), they may cause different cutaneous adverse
events, either of infectious, inflammatory or neoplastic origin
(Hernandez et al., 2013). Furthermore, targeted treatment
with BA is increasingly associated with a new class of
adverse events, the so-called paradoxical immune-mediated
inflammatory reactions. Paradoxical reactions (PR) are defined
by the development of inflammatory immune-mediated tissue
manifestations in IMID patients treated with targeted biological
agents. The skin is frequently involved by this paradoxical
inflammation, as in the case of plaque psoriasis developing in a
rheumatological patient during treatment with TNF-α inhibitors
(TNFi) (Viguier et al., 2009).
Cutaneous PR have been described as a class-effect of
targeted BA, especially TNFi, first in rheumatologic patients
and subsequently across all other indications, such as psoriasis
and inflammatory bowel-disease (IBD). Reports of different,
organ-specific PR are constantly increasing, as long-term
use of new anti-interleukin (anti-IL-6, -IL-17,-IL-12/23)
and first-to-second generation TNFi biosimilars is growing
(Toussirot and Aubin, 2016). Furthermore, cutaneous PR
represent an intriguing immunological and clinical dilemma,
whose unraveling may improve our knowledge of the
pathogenesis of chronic inflammatory diseases. These puzzling
cutaneous eruptions may also represent a new type of adverse
drug reactions in the era of precision medicine, resulting from the
interaction between targeted manipulation of cytokine-molecular
networks by BA and patient’s genetic predisposition (Cabaleiro
et al., 2016). We review the clinical spectrum of paradoxical
cutaneous inflammation induced by targeted BA in patients with
rheumatological disorders, discussing the current controversies
on classification, pathogenesis and clinical management.
Cutaneous Paradoxical Reactions:
Definition and Scope of the Problem
Psoriasis, and its clinical variants, represents the prototypical
cutaneous PR, as this was the first paradoxical reaction pattern
described in rheumatologic patients treated with the first-
generation BA, namely the TNFi. Therefore, most clinical
and experimental studies on PR have focused on paradoxical
psoriasis, providing the conceptual framework for the other
cutaneous PR. The literature on epidemiology of PRs in patients
treated with BA is scarce, as most of the clinical evidence derives
from retrospective studies, case series and reports. The estimated
prevalence of cutaneous PR ranges from 0.6 to 5.3% in patients
treated with TNFi (Sfikakis et al., 2005; Fouache et al., 2009;
Ko et al., 2009; Famenini and Wu, 2013; Bae et al., 2018). In a
registry-based observational study, the incidence of paradoxical
psoriasis in RA patients treated with TNFi has been estimated
in 1.04 per 1000 persons/years. Patients treated with TNFi
presented an incidence rate ratio (IRR) of 2.0–5.94 for the
onset of paradoxical psoriasis compared to patients treated with
conventional DMARDs (Hernandez et al., 2013). In RA patients,
the incidence of paradoxical psoriasis has been estimated in
one new case for every 550 patients treated with adalimumab
per year (Harrison et al., 2009). In the context of adverse
drug reaction, cutaneous PRs could be classified as uncommon-
to rare events. Typically, cutaneous PRs, such as paradoxical
psoriasis, can be induced de novo in rheumatologic patients
without a history of cutaneous inflammatory disease during
treatment with a BA. On the other hand, cutaneous PR can be an
exacerbation, with or without a change in clinical morphology,
of a pre-existing cutaneous inflammatory disease in a genetically-
predisposed patient. This is the case of paradoxical palmoplantar
pustular psoriasis developing during TNFi in a RA patient with
a history of plaque psoriasis. Key features supporting the causal
relationship between a skin PR and therapy with a BA are:
(a) the temporal association and (b) clinical outcome of the
PR after BA withdrawal. Cutaneous PR can occur at any time
during treatment with a BA, but more than 60% of cases of
paradoxical psoriasis has been reported to develop within the
first year of treatment (Brown et al., 2017). As observed in
cutaneous drug reactions, the cessation of the triggering “culprit”
BA determines clinical resolution or improvement of the skin PR.
Re-treatment, or drug re-challenge, with the same BA or related




In rheumatologic patients, cutaneous PRs induced by BA can
present with different clinical aspects and extent, involving
the skin, its appendages and transitional epithelial surfaces.
Cutaneous PRs, as defined previously, encompass a variety
of inflammatory manifestations/conditions, which can be
both treated and triggered with the same cytokine-targeted
BA. Cutaneous PRs reported in rheumatologic patients are
summarized in Figure 1 and include psoriasis and its spectrum of
clinical phenotypes (plaque, pustular, generalized, palmoplantar,
scalp, guttate, and inverse), hidradenitis suppurativa (HS),
neutrophilic dermatosis (the prototypical forms pyoderma
gangrenosum and Sweet’s syndrome) and granulomatous
skin disease (granuloma annulare, interstitial granulomatous
dermatitis, necrobiosis lipoidica, and sarcoidosis). Other
BA-inducible cutaneous inflammatory conditions, such as
atopic dermatitis, cutaneous vasculitis, drug-induced lupus
erythematosus and other allergic and hypersensitivity reactions
are not strictly considered “paradoxical” because their idiopathic
counterparts are not generally treated with these agents.
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FIGURE 1 | Classification and pathogenesis of cutaneous paradoxical reactions to biologic agents (∗) and their related key immune-response/cytokine patterns.
(1) TNF-α/type-1 IFN cytokine imbalance: pharmacological blockade of TNF-α by TNF-inhibitors (TNFi) determines uncontrolled activation of plasmacytoid dendritic
cells (pDCs), with sustained production of IFN-α. IFN-α drives paradoxical skin inflammation via downstream effectors cytokines, thus eliciting key cutaneous
immune response patterns→ clinical correlation: paradoxical psoriasis and psoriasiform eruptions.
(2) IFN-α induced spatial shift of activated innate immune cells and chemokine (C-X-C motif) receptor 3 (CXCR3) positive T-cells from extra-cutaneous tissue
compartments to the skin→ clinical correlation: de novo induction of psoriasiform eruptions and hidradenitis suppurativa.
(3) TNF-α/IL-10 cytokine imbalance and Tregs and TNFR2 imbalance→ clinical correlation: paradoxical cutaneous sarcoidosis and granulomatous disease.
(4) Shift in cutaneous immune response pattern→ clinical correlation: de novo induction of lichenoid, eczematous PR or change in psoriatic morphology
(plaque to pustular).
(∗) Based on expert opinion and on current available clinical and experimental evidence; cutaneous immune response patterns adapted
from Eyerich and Eyerich (2018).
Classification of inflammatory skin disease is traditionally
based on clinical morphology of primary and secondary
skin lesions in combination with a histological description
of epidermal-dermal tissue involvement and underlying
pathomechanisms (Dainichi et al., 2014). Adverse cutaneous
drug reactions also share similar classification systems, with
a combination of clinical descriptors of lesion morphology
(psoriasiform, bullous etc.) histological pattern (spongiotic,
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lichenoid/interface dermatitis, etc.) and underlying predominant
immunologic/hypersensitivity mechanism (type I-IV reaction)
(Isabwe et al., 2017). A recent trend in the classification of
inflammatory skin disease is to integrate clinicopathological data
with molecular-immunologic information, such as predominant
disease cell-subset, cytokine expression patterns and molecular
biomarkers (Inkeles et al., 2015; Garzorz-Stark and Lauffer,
2017) Recently, Eyerich and Eyerich (2018) summarized
the cutaneous immune-response patterns (Th1-, Th2-,
Th17/Th22- and Treg-cells and related cytokines) associated
with specific cutaneous-tissue response patterns (lichenoid,
eczematous/blistering, psoriatic, fibrogenic/granulomatous),
providing a molecular-pathophysiological approach to the
traditional, complex dermatological nosology. This conceptual
classification can be used for the description of cutaneous PR,
along with its prevalently associated clinical and immune-
response patterns, according to currently published data (refer
to Figure 1). According to its initial descriptions, cutaneous PRs
can be considered almost identical to its corresponding, “classic”
inflammatory skin disease in terms of clinical, histological and
immunological presentation. In the following sections we will
discuss some limitations of this concept, based on recent clinical
and experimental studies.
In BA-treated patients, the clinical picture of cutaneous PR
may vary from typical inflammatory skin lesions - clinically
and histological identical to its correspondent primary, non-
BA induced skin disease – to atypical inflammatory skin
manifestations, with “overlapping” clinical and histological
features. For example, paradoxical TNFi-induced psoriasis may
present with a wide clinical spectrum, with typical erythematous-
squamous or pustular lesions, clinically indistinguishable from
conventional plaque or pustular psoriasis, to atypical papulo-
squamous eruptions with “psoriasiform,” “eczematous” or
“lichenoid” lesion morphology (Succaria and Bhawan, 2017).
Correlation with histological aspects of lesional skin is crucial
for diagnosis of the PR type and differentiation with other
cutaneous adverse events. Moreover, in most published series
the spectrum of histological changes of a “psoriasiform”
paradoxical eruption is quite variable, ranging from typical
psoriatic pattern to lichenoid/interface dermatitis, pustular
folliculitis and eosinophil-rich perivascular dermatitis pattern.
Psoriatic alopecia has been recently described as a distinct
clinical phenotype of anti-TNF-α-induced, paradoxical
psoriasis, presenting with patchy, non-cicatricial alopecia
due to marked inflammatory involvement of the scalp skin
and hair follicles (Figure 1; Osório et al., 2012; George
et al., 2015). Histologically, features of both conventional
scalp psoriasis and alopecia areata have been observed
(Doyle et al., 2011).
Lichen planus (LP)-like or lichenoid skin eruptions are
characterized by an interface dermatitis histological pattern
and prominent Th1/ILC1 (type 1 innate lymphoid cell)-
IFN (interferon)-γ-biased immune-response. This skin-directed
cytotoxic reaction can be triggered by microbial antigens,
xenobiotics and drugs. Paradoxical, lichenoid eruptions have
been reported in RA and psoriatic arthritis (PsA) patients
during treatment with TNFi, variably involving the skin,
oral/genital mucosa, nails and hair-follicles (Vergara et al., 2002;
Asarch et al., 2009; Garcovich et al., 2010).
Hidradenitis suppurativa is a chronic, inflammatory disease
of the follicular epithelium, presenting with suppurative
lesions (nodules, abscesses, pustules, fistulas, sinus-tracts, and
hypertrophic scars) affecting the skin folds and anogenital
area. The cutaneous immune response pattern of primary
HS is characterized by Th17/ILC3 lymphocyte subset, with
strong IL-1β, TNF-α, IL-17 cytokine-signature, and peripheral
recruitment of IL-17-producing neutrophils and Th17-cells.
Paradoxical HS has been recently reported in patients with
RA or spondyloarthropathies (PsA, AS, SAPHO) during
long-term treatment (mean 25 months) with TNFi and
other BA (tocilizumab, rituximab) (Delobeau et al., 2016;
Faivre et al., 2016). Most patients presented known risk factors
for HS (smoking, overweight), but the relapse of paradoxical HS
after re-treatment with involved BA supports causality.
Pustular psoriasis and neutrophilic dermatoses (pyoderma
gangrenosum, Sweet syndrome) present a sterile pustule as
hallmark cutaneous lesion of neutrophilic inflammation.
Both “neutrophilic” inflammatory conditions share common
downstream inflammatory mediators, such as TNF-α,
IL-8, IL-17, IL12/23 and IL-36, which promote activation and
migration of neutrophils in the skin. Pyoderma gangrenosum,
the prototypical form of hypodermal neutrophilic, can be both
treated and paradoxically triggered by almost all the TNFi
(etanercept, adalimumab, infliximab, golimumab) (Vandevyvere
et al., 2007; Brunasso et al., 2010; Kowalzick et al., 2013; Marzano
et al., 2018; Skalkou et al., 2018).
Granulomatous skin conditions are a heterogenous group of
chronic inflammatory diseases, which include also reactive or
drug-induced processes. Reactive granulomatous skin eruptions
have a wide spectrum of clinical morphologies with several
clinical entities, such as interstitial granulomatous dermatitis
(IGD) and palisaded neutrophilic and granulomatous dermatitis
(PNGD). These reactive conditions can be triggered by systemic
inflammatory conditions, such as connective tissue disease and
the rheumatic disease, and by several drugs, such as TNFi (Deng
et al., 2006). Localized and generalized forms of granuloma
annulare have been reported in rheumatologic patients during
treatment with TNFi (Voulgari et al., 2008). Histological evidence
of dermal non-caseating granulomas is a hallmark of cutaneous
sarcoidosis, which can present several clinical-morphological
variants (Amber et al., 2015; Rosenbach and English, 2015).
Paradoxical development of sarcoidosis-like skin lesions has been
reported in rheumatologic patients treated with TNFi, especially
with etanercept (Dhaille et al., 2010; Massara et al., 2010;
Robicheaux Clementine et al., 2010; Lamrock and Brown, 2012;
Decock et al., 2017). In sum, cutaneous PR presents a wide
spectrum of clinical-histological reaction patterns.
PATHOGENESIS OF CUTANEOUS
PARADOXICAL INFLAMMATION
Since the initial descriptions, cutaneous inflammatory disease
presenting de novo in rheumatologic patients during treatment
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with potent, cytokine-targeted BA represented a clinical
and immunological conundrum. Considering the molecular
taxonomy of inflammatory skin disease, cutaneous PR can
be explained by the complex interplay between host-specific
factors (genetic predisposition) and BA-induced specific
shifts in cytokine and cellular immune-response patterns
( Palucka et al., 2005; Grine et al., 2015; Verwoerd et al., 2016).
According to current experimental data, cutaneous paradoxical
inflammation may result from different putative immune-
pathogenetic mechanisms (summarized in Figure 1), leading
to different types of clinical reactions. BA- induced immune-
pathogenesis of cutaneous PRs include one or more of the
following mechanisms as primum movens: (a) a cytokine
imbalance; (b) a shift in cutaneous immune response pattern; (c)
a spatial shift of activated innate or adaptive immune cells to the
skin; (d) imbalance or dysfunction of regulatory T-cells.
In the case of paradoxical psoriasis, a TNFi-induced cytokine
imbalance between TNF-α and type 1-Interferons (IFN-α) has
been reported as key-pathogenetic factor (Marzano et al., 2014).
Lesional skin of psoriasiform PR displayed an increased tissue-
expression of MxA (myxovirus-resistance protein A), i.e., type-1
interferon activity (de Gannes et al., 2007). Notably, systemic
treatment with recombinant IFN-α and topical application of
IFN-α inducers (imiquimod) are both able to elicit psoriatic skin
lesions in clinical and experimental models (Gilliet et al., 2004).
Continuous therapeutic TNF-α blockade thus cause a specific,
cutaneous cytokine imbalance, favoring development of
inflammatory plasmacytoid dendritic cells (pDCs) and increased
type-1 IFN production (Conrad et al., 2018). Increased IFN-
α-activity in turn determines abnormal trafficking and homing
of pDCs and innate immune cells to the skin, in an inflammatory
loop. Furthermore, in RA patients, treatment with TNFi has
been associated with increased expression of the chemokine
receptor CXCR3 on peripheral T-cells, potentially favoring
trafficking of activated T-cells to the skin (Aeberli et al., 2005).
This dysregulated, paradoxical innate immune response may
then translate clinically to paradoxical psoriasis in genetically
susceptible subjects.
Recent experimental studies raised several controversies
on the true nature of cutaneous PR, differentiating its
immune pathogenesis from their “classical,” non-paradoxical
counterparts. Stoffel et al. (2018) reported both psoriasiform
and eczematous PR to have a distinct lesional immune
response pattern, with a common strong Th1- and type-
1 IFN pattern, differing, respectively, from “classic” psoriasis
and eczema controls. In the same study, psoriasiform PR
presented an increased expression of type 1 IFN (IFN-α,
IFN-γ) and pro-inflammatory cytokines (IL-36, IL-19, IL-20),
whereas eczematous PR were associated with up-regulated Th-
2 cytokines (IL-13, IL-5) and IL-22 expression. In psoriasiform
PRs, the involvement of IL-1-(IL-36) and IL-17 (IL-17A) cytokine
families, sustaining a pro-inflammatory loop mechanism, has
been also reported in patients with IBD and psoriasis (Tillack
et al., 2014; Deubelbeiss et al., 2018). Finally, the group of
Gilliet et al. (2004) designed an experimental murine model
for paradoxical skin inflammation to support the differences
between paradoxical psoriasis and “classic” psoriasis. In this
model, induction of the “paradoxical” psoriasiform phenotype
is mainly driven by type 1 IFN expression and cutaneous
infiltration of pDCs due to temporal TNF-α/IFN imbalance.
The resulting paradoxical psoriasiform skin inflammation is
mostly independent from T-cells, i.e., from adaptive immune
responses, which is in contrast with “classical” psoriasis
(Conrad et al., 2018). BA-induced shifts of cutaneous immune
response patterns may then interact with host-specific genetic
risk variants for inflammatory cutaneous disease, promoting the
development of PRs. Indeed, preliminary studies support the
role of specific IL-23 receptor (IL-23R) gene polymorphisms
to be linked to anti-TNF-α-induced paradoxical psoriasis




Cutaneous PR occurring during treatment with BA represents
a clinical challenge in terms of differential diagnosis and
management. Clinical management should be aimed at treating
the cutaneous signs (eruption) and symptoms (pain, pruritus
etc.) while maintaining control of the underlying rheumatologic
condition. As discussed previously, the modification of
the anti-rheumatic treatment regimen, i.e., a treatment
suspension/withdrawal or therapeutic switch, is associated in
most cases with an improvement or resolution of the cutaneous
PR. Therefore, when approaching the rheumatologic patient
with a PR, the clinician should take into account several factors,
including: (a) the extent and severity of skin involved by the PR,
(b) the severity and activity of the background rheumatologic
condition, (c) the patient’s quality of life and comorbidities,
(d) the possible loss of efficacy of the culprit BA in the case
of cessation/retreatment, (e) the availability of alternative
treatment options for the rheumatologic condition. Dose-
reduction and discontinuation strategies of BA in rheumatologic
patients should be evaluated on a per-case basis by the treating
rheumatologist, as there are no definitive guidelines for the
management of cutaneous PR (van Herwaarden et al., 2014). In
the case of anti-TNF-α induced psoriasis, a practical treatment
algorithm has been initially proposed by Collamer et al. (2008)
and this can be adapted to other cases of cutaneous PRs as well.
In a BA-treated rheumatologic patient developing
inflammatory skin lesion a high-grade of suspicion for PR
should be taken. Interdisciplinary care should necessary include
evaluation by a dermatologist and lesional skin biopsy, to aid
clinical-histological correlations and differential diagnosis with
other cutaneous adverse events. The severity of cutaneous PR
can be graded with simple assessments, such as the extent
of body surface area (BSA) involved, symptom-based scores
(pruritus/pain intensity scores) and patient-reported outcomes
(dermatology life quality index [DLQI]). The addition of a
skin-directed therapy (topical or systemic) is a reasonable initial
strategy to manage the cutaneous PR and to maintain the patient
on treatment with the BA. Topical skin-directed therapies
(topical steroids, keratolytic agents, immunomodulators, vitamin
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D analogs) are a viable option for PR with mild (BSA < 5%)
to moderate (BSA 5–10%) skin involvement, such as localized
plaque psoriasis, lichenoid reactions or granulomatous lesions.
In the case of PR with moderate-to severe skin involvement
(>10% BSA), progressive course and/or high symptom-burden
(QoL impairment) treatment can be escalated with the addition
of UV-phototherapy or traditional systemic agents, such as
methotrexate, retinoids (acitretin), cyclosporine and systemic
steroids. Combination treatment regimens with systemic, skin-
directed agents and ongoing BA (for example TNFi) should be
carefully managed in close collaboration by the rheumatologist
and the dermatology consultant.
In the case of severe PR with extensive (>10% BSA), unstable
disease and/or high disease-burden, treatment with the BA
should be discontinued. For example, severe plaque psoriasis,
erythrodermic psoriasis, generalized pustular psoriasis or highly
pruritic lichenoid or eczematous eruption would necessarily lead
to discontinuation of anti-rheumatic treatment with a TNFi.
According to published studies, almost 50% of patients will
present an improvement or resolution of paradoxical skin lesions,
following withdrawal of the BA. Another 45% of patients with
anti-TNF-α induced psoriasis may present persistent or recurring
cutaneous lesions, despite BA discontinuation. The more severe
PR, such as generalized pustular psoriasis or psoriatic alopecia,
can run a persistent course, only with partial improvement, after
discontinuing the BA (Brown et al., 2017). Re-treatment with
the same BA, after cessation of the cutaneous PR, should be
evaluated on the basis of concomitant rheumatologic condition
and availability of alternative treatment options. There is a
substantial risk of recurrence of the cutaneous PR after re-
treatment with the same BA, but there is no strong evidence
in published studies (Wollina et al., 2008). Therapeutic switch
of the PR-triggering BA with another BA of the same class
(i.e., alternative TNFi) or of different class can be considered
in moderate-to severe cutaneous PR, to control the underlying
rheumatologic condition. Therapeutic switch to another BA is
also indicated in the severe, paradoxical psoriasis subtypes, as
in the case of generalized pustular psoriasis. Switching to a
new BA-class, for example from a TNFi to anti-IL6 treatment
(tocilizumab), is a common strategy in the management of
RA and has been also reported in the case of paradoxical
psoriasis (Rueda-Gotor et al., 2012; Shimizu et al., 2015;




The unexpected occurrence of paradoxical inflammation during
treatment with BA has emerged as a new type of drug-
related adverse event, with a complex pathophysiology. The
skin is one of the main organs affected by these reactions,
presenting with a wide spectrum of clinical and pathological
aspects. In rheumatologic patients, cutaneous PRs are frequent
and clinically relevant. Adequate clinical management of these
reactions is paramount to maintain control of background
rheumatologic disease and to improve drug survival of
BA. In some cases, therapeutic switch to another class
of BA or to new, small-molecule-based disease modifying
drugs is warranted to oppose paradoxical inflammation. The
understanding of these new types of adverse reactions will
hopefully shed light on the complex interactions between
host-specific factors (genetic predisposition), immune-mediated
comorbidities, immune-regulatory mechanisms and targeted
immune-modulation.
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